About: Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.22 (-4.65%)
ABSI NASDAQ Absci Corp
Absci Corp share price
ABSI price activity
Last Price
$9.230
Change (24hr)
-0.44 USD (-4.55%)
Volume
1.04M
Volume (4w avg)
-
Open
$9.45
Day Range
$9.23 - $9.45
Previous Close
$9.67
Last Trade
13 Oct, 4:57 pm GMT+0
Delayed
13 Oct, 4:57 pm GMT+0
ABSI price performance
Delayed
13 Oct, 4:57 pm GMT+0
ABSI Market Signals